Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 147

Showing 51-75 of 147 citing articles:

Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease
Qiuzhi Zhou, Weixia Wang, Chunchu Deng
Molecular Neurobiology (2025)
Open Access
Discovery of potent and selective PROTACs for the protein kinase LZK for the treatment of head and neck cancer
Meghri Katerji, K. Bergman, Eric Lindberg, et al.
Journal of Biological Chemistry (2025), pp. 108452-108452
Open Access
Advancing target validation with PROTAC technology
Margaret Spitz, Aseel Kashkush, Raphael I. Benhamou
Expert Opinion on Drug Discovery (2025)
Closed Access
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
Human MAPT knockin mouse models of frontotemporal dementia for the neurodegenerative research community
T Morito, Meng Qi, Naoko Kamano, et al.
Cell Reports Methods (2025), pp. 101024-101024
Open Access
BacPROTACs targeting Clp protease: a promising strategy for anti-mycobacterial drug discovery
Andressa Francielli Bonjorno, Aline Renata Pavan, Guilherme Fernandes, et al.
Frontiers in Chemistry (2024) Vol. 12
Open Access | Times Cited: 4
Potential acridinedione derivatives for the development of a heterobifunctional PROTAC for targeted degradation of PCSK9 protein
Vijay Kumar Bhardwaj, Rituraj Purohit
Applied Materials Today (2024) Vol. 38, pp. 102186-102186
Closed Access | Times Cited: 4
Novel gene therapy for drug-resistant melanoma: Synergistic combination of PTEN plasmid and BRD4 PROTAC-loaded lipid nanocarriers
Aishwarya Saraswat, Hari Priya Vemana, Vikas V. Dukhande, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 3, pp. 102292-102292
Open Access | Times Cited: 4
The future of machine learning for small-molecule drug discovery will be driven by data
G. J. DURANT, Fergus Boyles, Kristian Birchall, et al.
Nature Computational Science (2024) Vol. 4, Iss. 10, pp. 735-743
Closed Access | Times Cited: 4
Protein degraders - from thalidomide to new PROTACs
Takumi Ito
The Journal of Biochemistry (2023) Vol. 175, Iss. 5, pp. 507-519
Open Access | Times Cited: 10
Exploration of the Tunability of BRD4 Degradation by DCAF16Trans-labelling Covalent Glues
Muhammad Murtaza Hassan, Yen-Der Li, W Michelle, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 9
Targeting Proteasomes and the MHC Class I Antigen Presentation Machinery to Treat Cancer, Infections and Age-Related Diseases
Priyanka S. Rana, James J. Ignatz-Hoover, James J. Driscoll
Cancers (2023) Vol. 15, Iss. 23, pp. 5632-5632
Open Access | Times Cited: 9
Non-Markovian Dynamic Models Identify Non-Canonical KRAS-VHL Encounter Complex Conformations for Novel PROTAC Design
Yunrui Qiu, Rafal Wiewiora, Jesús A. Izaguirre, et al.
(2024)
Open Access | Times Cited: 3
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions
Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1089-1115
Open Access | Times Cited: 3
Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation
Junhyeong Yim, Jun‐Young Park, G. H. Kim, et al.
ChemMedChem (2024) Vol. 19, Iss. 22
Closed Access | Times Cited: 3
Advances in analytical technologies for emerging drug modalities and their separation challenges in LC-MS systems
M. Malarvannan, V. Ravichandiran, David Paul
Journal of Chromatography A (2024) Vol. 1732, pp. 465226-465226
Closed Access | Times Cited: 3
Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer
Yifan Feng, Chengjuan Chen, Anqi Shao, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 12, pp. 5091-5105
Open Access | Times Cited: 3
Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates
Yuying Shi, Gang Fan, Ruirong Tan, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 9
Open Access | Times Cited: 3
PROTAC-mediated activation, rather than degradation, of a nuclear receptor reveals complex ligand-receptor interaction network
Andrew D. Huber, Wenwei Lin, Shyaron Poudel, et al.
Structure (2024)
Closed Access | Times Cited: 3
Novel Prospects in Targeting Neurodegenerative Disorders via Autophagy
Shumayila Khan, Saurabh Upadhyay, Md. Imtaiyaz Hassan
European Journal of Pharmacology (2024) Vol. 984, pp. 177060-177060
Closed Access | Times Cited: 3
Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs
Daigo Asano, Hideo Takakusa, Daisuke Nakai
Pharmaceutics (2023) Vol. 16, Iss. 1, pp. 47-47
Open Access | Times Cited: 8
Harnessing PROTAC technology to combat stress hormone receptor activation
Mahshid Gazorpak, Karina M. Hugentobler, Dominique Paul, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Targeted Protein Degradation Systems: Controlling Protein Stability Using E3 Ubiquitin Ligases in Eukaryotic Species
Yoshitaka Ogawa, Taisei P. Ueda, Keisuke Obara, et al.
Cells (2024) Vol. 13, Iss. 2, pp. 175-175
Open Access | Times Cited: 2
Dysregulation of deubiquitination in breast cancer
Lili Kong, Xiaofeng Jin
Gene (2024) Vol. 902, pp. 148175-148175
Closed Access | Times Cited: 2
Huntingtin protein–protein interactions: From biology to therapeutic targets
Eduardo Silva Ramos, Todd M. Greco, Ileana M. Cristea, et al.
Elsevier eBooks (2024), pp. 159-186
Closed Access | Times Cited: 2

Scroll to top